PTC Therapeutics, Inc.(NASDAQ: PTCT) reported a revenues rise to $78.0 million during the fourth quarter of 2017 against the $25.2 million in pcp. Overall revenues rose to $194.4 million during the year against $82.7 million in pcp driven by the expanded commercial launch of Translarna™, the successful U.S. Emflaza™ launch and a $20 million milestone payment achieved from Roche for the initiation of the pivotal portion of the SMA clinical trial. Duchenne muscular dystrophy franchise generated $174 million dollars for 2017.
Translarna net product sales rose 63% to $41.0 million for the fourth quarter of 2017, while for the full year 2017, Translarna rose 78% yoy to $145.2 million in net product sales. Emflaza net product sales generated $17.0 million for the fourth quarter of 2017 and $28.8 million for the full year 2017.
On the other side, the FDA denied the group’s Translarna appeal, but recommended a possible path forward using the accelerate approval framework.
Meanwhile, the group continued to grow their DMD very tight which included expanding Translarna use around the world. Moreover, they acquired EMFLAZA based on its differentiated efficacy profile while offering access to patients in the United States.
Going forward, the group is well-positioned to continue to execute discovering, developing and commercializing differentiated therapies for rare disorders. Their commercial success with both Translarna as well as EMFLAZA indicates the group’s ability to address the unmet medical needs for DMD patients.
For 2018, the group expects their DMD franchise to generate between $260 million to $295 million. They see Translarna net product revenue in the range of $170 and $185 million. The group forecasts a 5-year (December 31, 2022) compound annual growth rate of 15% for net product revenues which is a solid growth on a year-over-year basis by enhancing penetration in current countries and pursuing opportunities for label expansion. Emflaza net product revenue is expected to be in the range of $90 and $110 million.
PTC Therapeutics stock generated over 7.6% on March 7th, 2018 (as of 9:47AM EST; Source: Google finance) leading to a total rise of over 72.4% in the last three months.